A retrospective study evaluating the effect of trastuzumab addition to carboplatin/paclitaxel on overall survival in patients with advanced-stage HER2/neu-overexpressing uterine serous carcinoma or carcinosarcoma
The addition of trastuzumab to frontline chemotherapy is effective in treating HER2-overexpressing uterine serous carcinoma and carcinosarcoma, particularly uterine carcinosarcoma. However, careful monitoring of adverse cardiac events is needed.
Authors
- Shih‐Tien Hsu (ORCID: https://orcid.org/0000-0003-0056-7894)
- Yu-Hsiang Shih
- Sheau-Feng Hwang (ORCID: https://orcid.org/0000-0002-7197-692X)
- Lou Sun (ORCID: https://orcid.org/0000-0001-5561-7110)
- Chih-Ku Liu
- Shao-Jing Wang (ORCID: https://orcid.org/0000-0001-7654-2699)
- Chun-Ting Fan
- Chien‐Hsing Lu (ORCID: https://orcid.org/0000-0001-7860-4320)
- Ting-Fang Lu (ORCID: https://orcid.org/0009-0000-1338-5614)
- Yen‐Fu Chen (ORCID: https://orcid.org/0000-0002-9446-2761)
Institutions
- Ling Tung University (TW)
- National Chung Hsing University (TW)
- Tunghai University (TW)
- Providence University (TW)
- China Medical University (TW)
- Taichung Veterans General Hospital (TW)
- Chung Shan Medical University (TW)
- National Yang Ming Chiao Tung University (TW)
Publication Details
- Journal
- BMC Medicine
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1186/s12916-025-03916-3
- Citations
- 6
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 6.27
Funders
- Taichung Veterans General Hospital